Issues related to health coverage and patient access to care. Issues related to prescription drug costs and affordability. Issues related to the No Surprises Act (Public Law 116-260)and patient protections. Issues related to agency funding for medical and cancer research. Issues related to H.R.4758/S.2372, The Accelerating Kids' Access to Care Act. Issues related to clinical trial diversity, including H.R. 3503/S.1701, the NIH Clinical Trial Diversity Act. Issues related to the pharmaceutical supply chain and drug shortages.
Issues related to blood cancer research for adult and pediatric populations. Issues related to the implementation of the Medicare Part D cap and smoothing provisions in the Inflation Reduction Act (Public Law 117-169). Issues related to H.R. 4758/S.2372, the Accelerating Kids' Access to Care Act.
Duration: January 1, 2016
to
present
General Issues: Health Issues , Medicare/Medicaid , Pharmacy , Budget/Appropriations
Spending: about $1,650,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2016: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), White House Office, Office of the Vice President of the United States
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Lisa Kountoupes
Deputy Asst. to the President & House Liaison, Special Assistant to the President for Legislative Affairs, Asst. Director for Legislative Affairs at OMB,Special Asst.to Undersecretary,Dept.of Energy,Policy Advisor to Chairman of Energy&Commerce Comm.
Lori Denham
Chief of Staff, Legislative Director, Legislative Assistant, Senior Policy Advisor, Communications Director, Staff Assistant - Rep. Cal Dooley, D-CA; Legislative Director - Rep. Darlene Hooley, D-OR
Julie Hershey Carr
Senior Policy Advisor, Legislative Director, Legislative Assistant - Rep. Joe Pitts, R-PA
Randi Reid
Legislative Director, Senior Legislative Assistant & Projects Director, Legislative Assistant - Senator Michael Enzi, R-WY; Legislative Director - Rep. Michael Burgess, R-TX
Rose Sullivan
Chief of Staff, Legislative Director, Legislative Assistant, Outreach Director, Constituent Services Advocate - Senator Amy Klobuchar, D-MN
David Peluso
Chief of Staff - Representative Cathy McMorris Rodgers, R-WA; Chief of Staff, Communications Director, Legislative Assistant, Deputy Press Secretary and Executive Assistant - Representative Gus Bilirakis, R-FL
MJ Kenny
Deputy Floor Director, Floor Assistant - Office of the Senate Democratic Whip; Legislative Aide, Legislative Correspondent - Senator Richard J. Durbin , D-IL
Mary Dee Beal
Policy Analyst,Senate Republican Policy Committee;Acting Chief of Staff to the Deputy Secretary,USDA;Senior Advisor to the Secretary,USDA;Legislative Director,Cong. Drew Ferguson,R-GA; Legis. Director, Legis. Assistant, Scheduler Cong. Austin Scott,R
Leslie Zelenko
Deputy Assistant Secretary for Legislation, Senior Advisor/Congressional Liaison-HHS; Legislative Director,Senior Legislative Assistant,Legislative Assistant,Legislative Correspondent-Cong. Mark Pocan, D-WI; Staff Assistant-Cong. Tammy Baldwin, D-WI
Denise Mousouris
n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Kountoupes Denham Carr & Reid, LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on April 9.
Original Filing: 301547593.xml
Lobbying Issues
Issues related to health coverage and patient access to care. Issues related to prescription drug costs and affordability. Issues related to the No Surprises Act (Public Law 116-260)and patient protections. Issues related to agency funding for medical and cancer research. Issues related to H.R.4758/S.2372, The Accelerating Kids' Access to Care Act. Issues related to clinical trial diversity, including H.R. 3503/S.1701, the NIH Clinical Trial Diversity Act. Issues related to the pharmaceutical supply chain and drug shortages.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to blood cancer research for adult and pediatric populations. Issues related to the implementation of the Medicare Part D cap and smoothing provisions in the Inflation Reduction Act (Public Law 117-169). Issues related to H.R. 4758/S.2372, the Accelerating Kids' Access to Care Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2023
In Q4, Kountoupes Denham Carr & Reid, LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on Jan. 16.
Original Filing: 301525141.xml
Lobbying Issues
Issues related to health coverage. Issues related to prescription drug costs and affordability. Issues related to the No Surprises Act and patient protections. Issues related to agency funding for medical and cancer research. Issues related to H.R.4758/S.2372, The Accelerating Kids' Access to Care Act. Issues related to clinical trial diversity, including H.R. 3503/S.1701, the NIH Clinical Trial Diversity Act. Issues related to the pharmaceutical supply chain and drug shortages.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to blood cancer research for adult and pediatric populations. Issues related to the implementation of the Medicare Part D cap and smoothing provisions in the Inflation Reduction Act (Public Law 117-169). Issues related to H.R. 4758/S.2372, the Accelerating Kids' Access to Care Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2023
In Q3, Kountoupes Denham Carr & Reid, LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on Oct. 11, 2023.
Original Filing: 301499439.xml
Lobbying Issues
Issues related to health coverage. Issues related to prescription drug costs and affordability. Issues related to the No Surprises Act and patient protections. Issues related to agency funding for medical and cancer research. Issues related to H.R.4758/S.2372, The Accelerating Kids' Access to Care Act. Issues related to clinical trial diversity, including H.R. 3503/S.1701, the NIH Clinical Trial Diversity Act. Issues related to the pharmaceutical supply chain and drug shortages. Issues related to ensuring access to affordable care.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to blood cancer research for adult and pediatric populations. Issues related to the implementation of the Medicare Part D cap and smoothing provisions in the Inflation Reduction Act (Public Law 117-169). Issues related to ensuring access to affordable care. Issues related to H.R. 4758/S.2372, the Accelerating Kids' Access to Care Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2023
In Q2, Kountoupes Denham Carr & Reid, LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on July 17, 2023.
Original Filing: 301478157.xml
Lobbying Issues
Issues related to health insurance, including Medicare. Issues related to prescription drug costs and affordability. Issues related to the No Surprises Act and patient protections. Issues related to agency funding for medical and cancer research. Issues related to The Accelerating Kids' Access to Care Act. Issues related to clinical trial diversity. Issues related to the pharmaceutical supply chain and drug shortages. Issues related to ensuring access to affordable care.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to blood cancer research for adult and pediatric populations. Issues related to the implementation of the Medicare Part D cap and smoothing provisions in the Inflation Reduction Act (Public Law 117-58). Issues related to ensuring access to affordable care. Issues related to the Accelerating Kids' Access to Care Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2023
In Q1, Kountoupes Denham Carr & Reid, LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on April 19, 2023.
Original Filing: 301458238.xml
Lobbying Issues
Issues related to health insurance, including Medicare, Medicaid and short term plans. Issues related to prescription drug costs and affordability. Issues related to the No Surprises Act and patient protections. Issues related to agency funding for medical and cancer research. Issues related to H.R. 3089/S.1544, the Accelerating Kids' Access to Care Act. Issues related to clinical trial diversity.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to health care coverage expansion. Issues related to blood cancer research for adult and pediatric populations. Issues related to the implementation of the Medicare Part D cap and smoothing provisions in the Inflation Reduction Act (Public Law 117-169).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2022
In Q4, Kountoupes Denham Carr & Reid, LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on Jan. 19, 2023.
Original Filing: 301432739.xml
Lobbying Issues
Issues related to health insurance, including Medicare, Medicaid and short term plans. Issues related to prescription drug costs and affordability. Issues related to the No Surprises Act and patient protections. Issues related to agency funding for medical and cancer research. Issues related to H.R. 3089/S. 1544, the Accelerating Kids' Access to Care Act and H.R. 7630/S.4120, the Childhood Cancer STAR Reauthorization Act. Issues related to clinical trial diversity including H.R. 5030/S.2706, DIVERSE Trials Act, in H.R. 6584, DEPICT Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to health care coverage expansion. Issues related to blood cancer research for adult and pediatric populations. Issues related to the implementation of the Medicare Part D cap and Smoothing provisions in the Inflation Reduction Act (Public Law 117-169).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2022
In Q3, Kountoupes Denham Carr & Reid, LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on Oct. 18, 2022.
Original Filing: 301407906.xml
Lobbying Issues
Issues related to health insurance, including Medicare, Medicaid and short term plans. Issues related to prescription drug costs and affordability. Issues related to the No Surprises Act and patient protections. Issues related to agency funding for medical and cancer research. Issues related to H.R. 3089/S. 1544, the Accelerating Kids' Access to Care Act. Issues related to clinical trial diversity including H.R. 5030/S. 2706, DIVERSE Trials Act, in H.R. 6584, DEPICT Act, and in user fees reauthorization legislation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to health care coverage expansion. Issues related to blood cancer research for adult and pediatric populations. Issues related drug pricing provisions in the Inflation Reduction Act (Public Law 117-169), including the Part D out-of-pocket cap.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2022
In Q2, Kountoupes Denham Carr & Reid, LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on July 15, 2022.
Original Filing: 301381096.xml
Lobbying Issues
Issues related to health insurance, including Medicare, Medicaid and short term plans. Issues related to prescription drug costs and affordability. Issues related to the No Surprises Act and patient protections. Issues related to agency funding for medical and cancer research. Issues related to H.R. 3089/S.1544, the Accelerating Kids' Access to Care Act. Issues related to funding for Consumer Assistance Programs in the Fiscal Year 2022 and Fiscal Year 2023 appropriations processes, including H.R. 2471, Consolidated Appropriations Act for Fiscal Year 2022. Issues related to clinical trial diversity including H.R. 5030/S. 2706 DIVERSE Trials Act and H.R. 6584, DEPICT Act, and in H.R. 7667, the Food and Drugs Amendments of 2022 and S.4348, the Food and Drug Administration Safety and Landmark Advancements Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to health care coverage expansion. Issues related to blood cancer research for adult and pediatric populations. Issues related to the Part D out-of-pocket cap.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2022
In Q1, Kountoupes Denham Carr & Reid, LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on April 18, 2022.
Original Filing: 301359093.xml
Lobbying Issues
Issues related to health insurance, including Medicare, Medicaid and short term plans. Issues related to prescription drug costs and affordability. Issues related to the No Surprises Act and patient protections. Issues related to agency funding for medical and cancer research. Issues related to H.R. 3089/S.1544, the Accelerating Kids' Access to Care Act. Issues related to funding for Consumer Assistance Programs in the Fiscal Year 2022 and Fiscal Year 2023 appropriations processes, including H.R. 2471, Consolidate Appropriations Act for Fiscal Year 2022. Issues related to clinical trial diversity including H.R. 5030/S. 2706 DIVERSE Trials Act and H.R. 6584, DEPICT Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to health care coverage expansion. Issues related to blood cancer research for adult and pediatric populations. Issues related to the Part D out-of-pocket cap.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2021
In Q4, Kountoupes Denham Carr & Reid, LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on Jan. 20, 2022.
Original Filing: 301336094.xml
Lobbying Issues
Issues related to health insurance, including Medicare, Medicaid and short term plans. Issues related to prescription drug costs and affordability. Issues related to the implementation of the No Surprises Act and patient protections. Issues related to agency funding for medical and cancer research. Issues related to H.R. 3089/S.1544, the Accelerating Kids' Access to Care Act. Issues related to funding for Consumer Assistance Programs in the FY2022 appropriations process. Issues related to H.R. 4385, the Cancer Drug Parity Act of 2021.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to health care coverage expansion. Issues related to blood cancer research for adult and pediatric populations. Issues related to the Part D out of pocket cap.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2021
In Q3, Kountoupes Denham Carr & Reid, LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on Oct. 20, 2021.
Original Filing: 301311058.xml
Lobbying Issues
Issues related to health insurance, including Medicare, Medicaid and short term plans. Issues related to prescription drug costs and affordability. Issues related to the implementation of the No Surprises Act and patient protections. Issues related to agency funding for medical and cancer research.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to health care coverage expansion. Issues related to blood cancer research for adult and pediatric populations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2021
In Q2, Kountoupes Denham Carr & Reid, LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on July 19, 2021.
Original Filing: 301280833.xml
Lobbying Issues
Issues related to health insurance, including Medicare, Medicaid and short term plans. Issues related to prescription drug costs and affordability. Issues related to COVID-relief legislation and non-profit loan eligibility. Issues related to the implementation of H. R. 133, Consolidated Appropriations Act for Fiscal Year 2021, including provisions regarding surprise billing and patient protections. Issues related to the implementation of H.R. 1319, the American Rescue Plan, including provisions related to Medicare. Issues related to consumer assistance programs in the Affordable Care Act. Issues related to agency funding for medical and cancer research.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) White House Office
Lobbying Issues
Issues related to a Medicare Part D out of pocket camp for beneficiaries including a policy to smooth out-of-pocket costs. Issues related to the implementation of H.R. 1319, the American Rescue Plan, including health coverage expansion. Issues related to blood cancer research for adult and pediatric populations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2021
In Q1, Kountoupes Denham Carr & Reid, LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on April 20, 2021.
Original Filing: 301263106.xml
Lobbying Issues
Issues related to health insurance, including Medicare, Medicaid and short term plans. Issues related to prescription drug costs and affordability. Issues related to COVID-relief legislation and non-profit loan eligibility. Issues related to the implementation of H. R. 133, Consolidated Appropriations Act for Fiscal Year 2021, including provisions regarding surprise billing and patient protections. Issues related to H.R. 1319, the American Rescue Plan, including provisions related to Medicaid.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to a Medicare Part D out of pocket camp for beneficiaries including a policy to smooth out-of-pocket costs. Issues related to H.R. 1319, the American Rescue Plan, including health coverage expansion. Issues related to blood cancer research for adult and pediatric populations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2020
In Q4, Kountoupes Denham Carr & Reid, LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on Jan. 17, 2021.
Original Filing: 301232719.xml
Lobbying Issues
Issues related to patient protections for blood cancer patients including the ban on pre-existing conditions and surprise medical billing. Issues related to prescription drug costs and affordability. Issues related to COVID-relief legislation and non profit loan eligibility. Issues related to H.R. 133, Consolidated Appropriations Act for Fiscal Year 2021, including provisions regarding surprise billing and patient protections.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to a Medicare Part D out of pocket cap for beneficiaries, including a policy to smooth out-of-pocket costs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers. Issues related to Presidential Executive Orders regarding drug pricing.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2020
In Q3, Kountoupes Denham Carr & Reid, LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on Oct. 13, 2020.
Original Filing: 301209316.xml
Lobbying Issues
Issues related to patient protections for blood cancer patients including the ban on pre-existing conditions and surprise medical billing. Issues related to prescription drug costs and affordability. Issues related to COVID-relief legislation and non profit loan eligibility.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to a Medicare Part D out of pocket cap for beneficiaries, including a policy to smooth out-of-pocket costs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers. Issues related to Presidential Executive Orders regarding drug pricing.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
2nd Quarter, 2020
In Q2, Kountoupes Denham Carr & Reid, LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on July 16, 2020.
Original Filing: 301189691.xml
Lobbying Issues
Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R. 1730/S.741, the Cancer Drug Parity Act of 2019. Issues related to patient protections for blood cancer patients. Issues related to pediatric cancer. Issues related to surprise medical billing. Issues related to the implementation of H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including patient protections for medical treatment. Issues related to H.R. 6800, the HEROES Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to a Medicare Part D out of pocket cap for beneficiaries, including a policy to smooth out-of-pocket costs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
1st Quarter, 2020
In Q1, Kountoupes Denham Carr & Reid, LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on April 19, 2020.
Original Filing: 301172746.xml
Lobbying Issues
Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R. 1730/S.741, the Cancer Drug Parity Act of 2019. Issues related to patient protections for blood cancer patients. Issues related to pediatric cancer. Issues related to surprise medical billing. Issues related to H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including patient protections for medical treatment.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to a Medicare Part D out of pocket cap for beneficiaries, including a policy to smooth out-of-pocket costs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
4th Quarter, 2019
In Q4, Kountoupes Denham Carr & Reid, LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on Jan. 17, 2020.
Original Filing: 301109828.xml
Lobbying Issues
Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R. 1730/S.741, the Cancer Drug Parity Act of 2019. Issues related to patient protections for blood cancer patients. Issues related to insurance market stabilization. Issues related to pediatric cancer. H. R. 1865, the Further Consolidated Appropriations Act of 2020.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to a Medicare Part D out of pocket cap for beneficiaries, including a policy to smooth out-of-pocket costs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to blood cancer research funding included in the FY 2020 Labor-HHS and Department of Defense Appropriations Bills. H. R. 1865, the Further Consolidated Appropriations Act of 2020.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2019
In Q3, Kountoupes Denham Carr & Reid, LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on Oct. 17, 2019.
Original Filing: 301068550.xml
Lobbying Issues
Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R. 1730/S.741, the Cancer Drug Parity Act of 2019. Issues related to patient protections for blood cancer patients. Issues related to insurance market stabilization. Issues related to pediatric cancer.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to a Medicare Part D out of pocket cap for beneficiaries, including a policy to smooth out-of-pocket costs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to blood cancer research funding included in the FY 2020 Labor-HHS and Department of Defense Appropriations Bills.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2019
In Q2, Kountoupes Denham Carr & Reid, LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on July 15, 2019.
Original Filing: 301045861.xml
Lobbying Issues
Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R. 1730/S.741, the Cancer Drug Parity Act of 2019. Issues related to patient protections for blood cancer patients. Issues related to insurance market stabilization. Issues related to pediatric cancer.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Medicare Part D as related to blood cancer beneficiaries.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to blood cancer research funding included in the FY 2020 Labor-HHS and Department of Defense Appropriations Bills.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2019
In Q1, Kountoupes Denham Carr & Reid, LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on April 17, 2019.
Original Filing: 301026871.xml
Lobbying Issues
Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R. 1409, the Cancer Drug Parity Act of 2017. Issues related to patient protections for blood cancer patients. Issues related to insurance market stabilization. Issues related to pediatric cancer.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Medicare Part D as related to blood cancer beneficiaries.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to blood cancer research funding included in the FY 2020 Labor-HHS and Department of Defense Appropriations Bills.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2018
In Q4, Kountoupes Denham Carr & Reid, LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on Jan. 22, 2019.
Original Filing: 301014205.xml
Lobbying Issues
Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R.1409 the Cancer Drug Parity Act of 2017. Issues related to patient protections for blood cancer patients. Issues related to insurance market stabilization. Issues related to pediatric cancer, including H. R. 820, the Childhood Cancer STAR Act, and it's Senate companion S.292, the Childhood Cancer Survivorship, Treatment Access, and Research Act of 2018. Issues related to Health Savings Accounts. Issues related to Short-Term Limited Duration health insurance plans.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Medicare Part D as related to blood cancer beneficiaries.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to blood cancer research funding included in the FY 2019 Labor-HHS and Department of Defense Appropriations Bills.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2018
In Q3, Kountoupes Denham Carr & Reid, LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on Oct. 17, 2018.
Original Filing: 300987326.xml
Lobbying Issues
Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R.1409 the Cancer Drug Parity Act of 2017. Issues related to patient protections for blood cancer patients. Issues related to insurance market stabilization. Issues related to pediatric cancer, including H. R. 820, the Childhood Cancer STAR Act, and it's Senate companion S.292, the Childhood Cancer Survivorship, Treatment Access, and Research Act of 2018. Issues related to Health Savings Accounts. Issues related to Short-Term Limited Duration health insurance plans.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Medicare Part D as related to blood cancer beneficiaries.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to blood cancer research funding included in the FY 2019 Labor-HHS and Department of Defense Appropriations Bills.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2018
In Q2, Kountoupes Denham Carr & Reid, LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on July 12, 2018.
Original Filing: 300964347.xml
Lobbying Issues
Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R.1409 the Cancer Drug Parity Act of 2017. Issues related to patient protections for blood cancer patients. Issues related to insurance market stabilization. Issues related to pediatric cancer, including H. R. 820, the Childhood Cancer STAR Act. Issues related to "right-to-try" legislation, including H. R. 878 and S.204 the Right to Try Act of 2017. Issues related to Health Savings Accounts. Issues related to Short-Term Limited Duration health insurance plans.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Medicare Part D as related to blood cancer beneficiaries.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to blood cancer research funding included in the FY 2019 Labor-HHS and Department of Defense Appropriations Bills.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2018
In Q1, Kountoupes Denham Carr & Reid, LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on April 20, 2018.
Original Filing: 300954735.xml
Lobbying Issues
Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R.1409 the Cancer Drug Parity Act of 2017. Issues related to patient protections for blood cancer patients. Issues related to insurance market stabilization. Issues related to pediatric cancer, including H. R. 820, the Childhood Cancer STAR Act. Issues related to "right-to-try" legislation, including H. R. 878 and S.204 the Right to Try Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Medicare Part D as related to blood cancer beneficiaries.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to blood cancer research funding included in H. R. 1625, the Consolidated Appropriations Act of 2018.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2017
In Q4, Kountoupes Denham Carr & Reid, LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on Jan. 19, 2018.
Original Filing: 300928801.xml
Lobbying Issues
Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R.1409 the Cancer Drug Parity Act of 2017. Issues related to patient protections for blood cancer patients. Issues related to insurance market stabilization. Issues related to pediatric cancer, including H. R. 820, the Childhood Cancer STAR Act. Issues related to "right-to-try" legislation, including H. R. 878 the Right to Try Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Medicare Part D as related to blood cancer beneficiaries.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2017
In Q3, Kountoupes Denham Carr & Reid, LLC (formerly reporting as Kountoupes Denham LLC) lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on Oct. 20, 2017.
Original Filing: 300913214.xml
Lobbying Issues
Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R.1409 the Cancer Drug Parity Act of 2017. Issues related to patient protections for blood cancer patients. House and Senate efforts to repeal and replace the Affordable Care Act including amendments to the H. R. 1628, the Affordable Health Care Act of 2017, versions of the Better Care Reconciliation Act, as well as the Graham-Cassidy proposal. Issues related to insurance market stabilization. Issues related to pediatric cancer, including H. R. 820, the Childhood Cancer STAR Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Medicare Part D as related to blood cancer beneficiaries.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2017
In Q2, Kountoupes Denham LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on July 19, 2017.
Original Filing: 300890424.xml
Lobbying Issues
Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R.1409 the Cancer Drug Parity Act of 2017 and the Better Care Reconciliation Act (BCRA). Issues related to patient protections for blood cancer patients. H. R. 1628, the American Health Care Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Medicare Part D as related to blood cancer beneficiaries.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to protecting patients' access to blood cancer treatment by addressing issues related to specialty drug tiers.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2017
In Q1, Kountoupes Denham LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on April 20, 2017.
Original Filing: 300874581.xml
Lobbying Issues
Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies. Issues related to patient protections for blood cancer patients. H. R. 1628, the American Health Care Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Medicare Part D as related to blood cancer beneficiaries.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to protecting patients' access to blood cancer treatment by addressing issues related to specialty drug tiers.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2016
In Q4, Kountoupes Denham LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on Jan. 18, 2017.
Original Filing: 300848902.xml
Lobbying Issues
Issues related to blood cancer research diagnosis, treatment and cures, including coverage and reimbursement of cancer treatment therapies. Issues related to H. R. 6, 21st Century Cures Act and the Senate Innovation for Healthier Americans Initiative. H. R. 2739, S. 1596, the Cancer Drug Coverage Parity Act. Outreach regarding the "National Cancer Moonshot" initiative. Education and outreach regarding the FDA's Acute Myeloid Leukemia (AML) Master Trial. Issues related to patient protections and the Affordable Care Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Medicare Part D as related to blood cancer beneficiaries including H.R. 2624, S.1488, the Part D Beneficiary Appeals Fairness Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2016
In Q3, Kountoupes Denham LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on Oct. 19, 2016.
Original Filing: 300833735.xml
Lobbying Issues
Issues related to blood cancer research diagnosis, treatment and cures, including coverage and reimbursement of cancer treatment therapies. Issues related to H. R. 6, 21st Century Cures Act and the Senate Innovation for Healthier Americans Initiative. H. R. 2739, S. 1596, the Cancer Drug Coverage Parity Act. Outreach regarding the "National Cancer Moonshot" initiative.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Medicare Part D as related to blood cancer beneficiaries including H.R. 2624, S.1488, the Part D Beneficiary Appeals Fairness Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2016
Kountoupes Denham LLC amended a lobbying report for representation of The Leukemia and Lymphoma Society in Q22016 on July 19, 2016.
Original Filing: 300814026.xml
Lobbying Issues
Issues related to blood cancer research diagnosis, treatment and cures, including coverage and reimbursement of cancer treatment therapies. Issues related to H. R. 6, 21st Century Cures Act and the Senate Innovation for Healthier Americans Initiative. H. R. 2739, S. 1596, the Cancer Drug Coverage Parity Act. Outreach regarding the "National Cancer Moonshot" initiative.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of the Vice President of the United States Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to Medicare Part D as related to blood cancer beneficiaries including H.R. 2624, S.1488, the Part D Beneficiary Appeals Fairness Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2016
In Q2, Kountoupes Denham LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on July 18, 2016.
Original Filing: 300811582.xml
Lobbying Issues
Issues related to blood cancer research diagnosis, treatment and cures, including coverage and reimbursement of cancer treatment therapies. Issues related to H. R. 6, 21st Century Cures Act and the Senate Innovation for Healthier Americans Initiative. H. R. 2739, S. 1596, the Cancer Drug Coverage Parity Act. Outreach regarding the "National Cancer Moonshot" initiative.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of the Vice President of the United States
Lobbying Issues
Issues related to Medicare Part D as they are related to blood cancer patients including H.R. 2624, S.1488, the Part D Beneficiary Appeals Fairness Act.
1st Quarter, 2016
In Q1, Kountoupes Denham LLC lobbied for The Leukemia and Lymphoma Society , earning $50,000. The report was filed on April 20, 2016.
Original Filing: 300799156.xml
Lobbying Issues
Issues related to blood cancer research diagnosis, treatment and cures, including coverage and reimbursement of cancer treatment therapies. Issues related to H. R. 6, 21st Century Cures Act and the Senate Innovation for Healthier Americans Initiative. H. R. 2739, S. 1596, the Cancer Drug Coverage Parity Act. Outreach regarding the "National Cancer Moonshot" initiative.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Office of the Vice President of the United States
Lobbying Issues
Part D Beneficiary Appeals Fairness Act.
1st Quarter, 2016
Kountoupes Denham (formerly reporting as Kountoupes Consulting, LLC) filed a lobbying registration on March 1, 2016 to represent The Leukemia and Lymphoma Society, effective Jan. 1, 2016.
Original Filing: 300787073.xml
Issue(s) they said they’d lobby about: Issues related to blood cancer research diagnosis, treatment and cures. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate